Adaptive Phage Therapeutics, Inc.

About Adaptive Phage Therapeutics, Inc.

Adaptive Phage Therapeutics, Inc. (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. In 2016, APT entered into a collaborative research and development agreement (CRADA) with the Naval Medical Research Center (NMRC) and has negotiated worldwide exclusive rights to NMRC’s innovative system for phage/pathogen rapid matching (patents pending), as well as proprietary datasets, and PhageBank™.
YEAR FOUNDED:
2016
LEADERSHIP:
CEO: Greg Merril